留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

慢性阻塞性肺疾病治疗药物研究进展

罗志成 吴国振 袁星

罗志成, 吴国振, 袁星. 慢性阻塞性肺疾病治疗药物研究进展[J]. 药学实践与服务, 2017, 35(3): 201-204,242. doi: 10.3969/j.issn.1006-0111.2017.03.003
引用本文: 罗志成, 吴国振, 袁星. 慢性阻塞性肺疾病治疗药物研究进展[J]. 药学实践与服务, 2017, 35(3): 201-204,242. doi: 10.3969/j.issn.1006-0111.2017.03.003
LUO Zhicheng, WU Guozhen, YUAN Xing. Research progress in drugs for chronic obstructive pulmonary disease therapy[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(3): 201-204,242. doi: 10.3969/j.issn.1006-0111.2017.03.003
Citation: LUO Zhicheng, WU Guozhen, YUAN Xing. Research progress in drugs for chronic obstructive pulmonary disease therapy[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(3): 201-204,242. doi: 10.3969/j.issn.1006-0111.2017.03.003

慢性阻塞性肺疾病治疗药物研究进展

doi: 10.3969/j.issn.1006-0111.2017.03.003

Research progress in drugs for chronic obstructive pulmonary disease therapy

  • 摘要: 慢性阻塞性肺疾病(COPD)是一种气流受限且不完全可逆,同时病情进行性加重的慢性呼吸系统疾病。COPD病理机制复杂,病症主要包括肺功能降低、气道及肺组织慢性炎症、咳嗽、消瘦、活动量减少等。以往临床上一般采用支气管扩张剂和抗炎药物对COPD进行治疗,随着对该疾病病理机制的深入研究,抗氧化治疗也已逐渐应用于临床。笔者现对包括支气管扩张剂、抗炎药物及抗氧化治疗药物在内的COPD治疗药物的研究进展进行综述。
  • [1] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组. 慢性阻塞性肺疾病诊治指南(2013年修订版)(二)[J]. 全科医学临床与教育, 2013, 36(6): 484-491.
    [2] Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010[J]. Lancet, 2012, 380(9859): 2095-2128.
    [3] 丁 宁, 王 胜. 慢性阻塞性肺疾病发病机制最新研究进展[J]. 临床肺科杂志, 2016, 21(1): 133-136.
    [4] 徐庆庆, 李向阳. 抗胆碱能药物在慢性阻塞性肺疾病中的临床应用[J]. 中国医药指南, 2015, 13(29): 37-39.
    [5] 任艳平, 石 蕊, 张 睿,等. 噻托溴铵治疗慢性阻塞性肺疾病有效性和安全性的Meta分析[J]. 中国药房, 2015, 26(21): 2947-2949.
    [6] 夏玲红, 孙 黎, 金冠钦,等. 治疗慢性阻塞性肺病新药阿地溴铵[J]. 中国新药杂志, 2013, 22(5): 499-501.
    [7] Jones PW, Singh D, Bateman ED, et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the anttainstudy[J]. Eur Respir J, 2012, 40(4): 830-836.
    [8] Kerwin E, Hébert J, Gallagher N, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the glow2 study[J]. Eur Respir J, 2012, 40(5): 1106-1114.
    [9] Kew K. Long-acting beta2-agonists for chronic obstructive pulmonary disease[J]. Cochrane Database Syst Rev, 2006, 3(3): 117-118.
    [10] Kornmann O, Dahl R, Centanni S, et al. Once daily indacaterol versus twice daily salmeterol for COPD: a placebo controlled comparison[J]. Euro Respir J, 2011, 37(2): 273-279.
    [11] 李 媛, 林 青. 茶碱类药物的研究进展及应用[J]. 中国医药指南, 2013, 11(4): 421-422.
    [12] Iiboshi H, Ashitani J, Katoh S. Long-term treatment with theophylline reduces neutrophils, interleukin-8 and tumor necrosis factor-α in the sputum of patients with chronic obstructive pulmonary disease[J]. Pulm Pharmacol Ther, 2007, 20(1): 46-51.
    [13] Barnes PJ. Theophylline: new perspectives for an old drug[J]. Am J Respir Crit Care Med, 2003, 167(6): 813-818.
    [14] 赵新云, 孔 辉, 解卫平. 炎症反应与慢性阻塞性肺疾病肺功能分级[J]. 国际呼吸杂志, 2013, 33(17): 1343-1346.
    [15] 钟佰强, 钱丽芬, 黄宝贤,等. 不同剂量糖皮质激素对慢性阻塞性肺疾病患者急性加重期炎性介质的影响及临床意义[J]. 中华老年医学杂志, 2014, 33(4): 376-379.
    [16] Battaglia S, Cardillo I, Lavorini F, et al. Safety considerations of inhaled corticosteroids in the elderly[J]. Drugs Aging, 2014, 31(11): 787-796.
    [17] 赵 焕, 石寒冰, 毕红霞. 布地奈德联合福莫特罗雾化吸入治疗慢性阻塞性肺疾病的临床疗效观察[J]. 中国全科医学, 2013, 15(35): 4219-4221.
    [18] Yan JH, Gu WJ, Pan L. Efficacy and safety of roflumilast in patients with stable chronic obstructive pulmonary disease: a meta-analysis[J].Pulm Pharmacol Ther, 2014, 27(1): 83-89.
    [19] 宋 毅, 徐莉琼, 李 婵,等. 孟鲁司特治疗慢性阻塞性肺病65例疗效观察[J]. 四川医学, 2012, 33(3): 436-438.
    [20] 李 强, 邹小新, 饶常红. 孟鲁司特联合噻托溴铵治疗慢性阻塞性肺疾病疗效的研究[J]. 重庆医学, 2013, 42(19): 2278-2280.
    [21] Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD[J]. N Engl J Med, 2011, 365(8): 689-698.
    [22] Neukamm A, HΦiseth AD, Einvik G, et al. Rosuvastatin treatment in stable chronic obstructive pulmonary disease (RODEO): a randomized controlled trial[J].J Intern Med, 2014, 278(1): 59-67.
    [23] 王翠茹, 李 玲, 韩云霞,等. 慢性阻塞性肺疾病发病机制的研究进展[J]. 当代医学, 2011, 17(32): 19-20.
    [24] Santus P, Corsico A, Solidoro P, et al. Oxidative stress and respiratory system: pharmacological and clinical reappraisal of N-acetylcysteine[J]. COPD, 2014, 11(6): 705-717.
    [25] Tse HN, Raiteri L, Wong KY, et al. High-dose N-acetylcysteine in stable chronic obstructive pulmonary disease: the 1 year, double-blind, randomized, placebo-controlled HIACE study[J]. Chest, 2013, 144(1): 106-118.
    [26] 张 瑞. 盐酸氨溴索雾化对COPD患者氧化应激的影响[J]. 临床肺科杂志, 2013, 18(5): 894-895.
    [27] Esposito A, Valentino MR, Bruzzese D, et al. Effect of carbocisteine in prevention of exacerbation of chronic obstructive pulmonary disease (CAPRI study): an observational study[J].Pulm Pharmacol Ther, 2016, 37(1): 85-88.
    [28] Sussan TE, Rangasamy T, Blake DJ, et al. Targeting Nrf2 with the triterpenoid CDDO-imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice[J].Proc Natl Acad Sci USA, 2009, 106(1): 250-255.
    [29] Yu W, Fu YC, Wang W. Cellular and molecular effects of resveratrol in health and disease[J].J Cell Biochem, 2012, 113(3): 752-759.
    [30] He X, Wang L, Szklarz G, et al. Resveratrol inhibits paraquat-induced oxidative stress and fibrogenic response by activating the nuclear factor erythroid 2-related factor 2 pathway[J].J Pharmacol Exp Ther, 2012, 342(1): 81-90.
    [31] Youn GS, Kwon DJ, Ju SM, et al. Curcumin ameliorates TNF-α-induced ICAM-1 expression and subsequent THP-1 adhesiveness via the induction of heme oxygenase-1 in the HaCaT cells[J].BMB Rep, 2013, 46(8): 410-415.
  • 加载中
计量
  • 文章访问数:  2601
  • HTML全文浏览量:  250
  • PDF下载量:  1192
  • 被引次数: 0
出版历程
  • 收稿日期:  2016-09-27
  • 修回日期:  2017-02-23

慢性阻塞性肺疾病治疗药物研究进展

doi: 10.3969/j.issn.1006-0111.2017.03.003

摘要: 慢性阻塞性肺疾病(COPD)是一种气流受限且不完全可逆,同时病情进行性加重的慢性呼吸系统疾病。COPD病理机制复杂,病症主要包括肺功能降低、气道及肺组织慢性炎症、咳嗽、消瘦、活动量减少等。以往临床上一般采用支气管扩张剂和抗炎药物对COPD进行治疗,随着对该疾病病理机制的深入研究,抗氧化治疗也已逐渐应用于临床。笔者现对包括支气管扩张剂、抗炎药物及抗氧化治疗药物在内的COPD治疗药物的研究进展进行综述。

English Abstract

罗志成, 吴国振, 袁星. 慢性阻塞性肺疾病治疗药物研究进展[J]. 药学实践与服务, 2017, 35(3): 201-204,242. doi: 10.3969/j.issn.1006-0111.2017.03.003
引用本文: 罗志成, 吴国振, 袁星. 慢性阻塞性肺疾病治疗药物研究进展[J]. 药学实践与服务, 2017, 35(3): 201-204,242. doi: 10.3969/j.issn.1006-0111.2017.03.003
LUO Zhicheng, WU Guozhen, YUAN Xing. Research progress in drugs for chronic obstructive pulmonary disease therapy[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(3): 201-204,242. doi: 10.3969/j.issn.1006-0111.2017.03.003
Citation: LUO Zhicheng, WU Guozhen, YUAN Xing. Research progress in drugs for chronic obstructive pulmonary disease therapy[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(3): 201-204,242. doi: 10.3969/j.issn.1006-0111.2017.03.003
参考文献 (31)

目录

    /

    返回文章
    返回